Drug intelligence / Profile preview

LNF2102

Development stage: Unknown
Lead developer: Shandong New Time Pharmaceutical
Administration: Ophthalmic

Overview

LNF2102 is a **biological drug** developed by Shandong New Time Pharmaceutical and is in Phase 1 clinical trials for the treatment of **advanced malignant solid neoplasms**. The available information confirms it is being evaluated for safety, tolerability, preliminary efficacy, pharmacokinetics, and immunogenicity in patients with advanced solid tumors. Detailed molecular mechanism, specific modality beyond "biological product", and targets are not disclosed in publicly available data as of the last update[1].

Targets

FGFR2b (Fibroblast growth factor receptor 2 IIIb isoform)

Beyond the preview

Go deeper on LNF2102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LNF2102.

Explore the full profile